Gg_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":199418654,"tweetId":"199418654","gmtCreate":1620725817678,"gmtModify":1634196817973,"author":{"id":3576228066699478,"idStr":"3576228066699478","authorId":3576228066699478,"authorIdStr":"3576228066699478","name":"jiajia321","avatar":"https://static.tigerbbs.com/b78078be18e2c45700ab0923b697b201","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Gg</body></html>","htmlText":"<html><head></head><body>Gg</body></html>","text":"Gg","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/199418654","repostId":1128439536,"repostType":4,"repost":{"id":"1128439536","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620721615,"share":"https://www.laohunote.com/m/news/1128439536?lang=zh_CN&edition=full","pubTime":"2021-05-11 16:26","market":"us","language":"en","title":"Novavax trades lower on delayed regulatory submission for COVID-19 vaccine<blockquote>由于 COVID-19 疫苗监管提交延迟，Novavax 股价走低</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1128439536","media":"Tiger Newspress","summary":"(May 11) Confirming the media reports, Novavx(NASDAQ:NVAX) has delayed its plans for regulatory subm","content":"(May 11)&nbsp;Confirming the media reports, Novavx(NASDAQ:NVAX)&nbsp;has delayed its plans for&nbsp;regulatory submissions for the COVID-19 vaccine in the U.S. U.K.and European Medicines Agency (EMA).<blockquote>（5 月 11 日）证实媒体报道，Novavx（纳斯达克股票代码：NVAX）已推迟向美国、英国和欧洲药品管理局 (EMA) 提交 COVID-19 疫苗监管文件的计划。</blockquote>The company now intends to file authorization for NVX-CoV2373 in Q3 2021. Novavax has beaten the consensus with its Q1 2021 financials, but the vaccine setback has hurt the shares which have&nbsp;lost nearly&nbsp;13%&nbsp;in pre-market now.<blockquote>该公司目前打算在 2021 年第三季度提交 NVX-CoV2373 的授权。Novavax 的 2021 年第一季度财务数据超出了市场普遍预期，但疫苗的挫折损害了该股，该股目前在盘前已下跌近 13%。</blockquote>Novavax has completed the enrollment of the pivotal Phase 3 trials in the U.S. and Mexico, and the final analysis is expected to be reported in Q2 2021, the company said.<blockquote>该公司表示，Novavax 已完成美国和墨西哥关键 3 期试验的注册，最终分析预计将于 2021 年第二季度报告。</blockquote>The global manufacturing capacity for the vaccine has been revised up to 100M doses per month by the end of Q3 2021, and a capacity of 150M doses per month is expected by Q4 2021.<blockquote>到2021年第三季度末，该疫苗的全球生产能力已修订至每月1亿剂，预计到2021年第四季度将达到每月1.5亿剂。</blockquote>Revenue has risen ~149x to ~$447M due to increased development work relating to NVX-CoV2373 for services performed under the agreements signed with the U.S. government and Coalition for Epidemic Preparedness Innovations.<blockquote>由于根据与美国政府和流行病防范创新联盟签署的协议，与 NVX-CoV2373 相关的开发工作有所增加，收入增长了约 149 倍，达到约 4.47 亿美元。</blockquote>With R&amp;D expenses rising ~34.9x from the previous quarter to $593M, the net loss in Q1 2021 has expanded ~8.6x from the previous year to $223M.<blockquote>随着R&amp;D费用比上一季度增长约34.9倍，达到5.93亿美元，2021年第一季度的净亏损比上一年扩大约8.6倍，达到2.23亿美元。</blockquote>However, cash and equivalents have jumped to $2B compared to $806M in 2020-year end primarily due to $772M received from advance purchase agreements recognized as deferred revenue.<blockquote>然而，现金及等价物已从 2020 年底的 8.06 亿美元跃升至 20 亿美元，这主要是由于从确认为递延收入的预购协议中收到的 7.72 亿美元。</blockquote>The previously announced timeline for the EUA (Emergency&nbsp;Use Authorization) submission was Q2 2021.<blockquote>之前宣布的EUA（紧急使用授权）提交时间表是2021年第二季度。</blockquote><img src=\"https://static.tigerbbs.com/68316eaff6bc94d588de0dd64c00496b\" tg-width=\"786\" tg-height=\"494\"><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax trades lower on delayed regulatory submission for COVID-19 vaccine<blockquote>由于 COVID-19 疫苗监管提交延迟，Novavax 股价走低</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax trades lower on delayed regulatory submission for COVID-19 vaccine<blockquote>由于 COVID-19 疫苗监管提交延迟，Novavax 股价走低</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nTiger Newspress \n2021-05-11 16:26\n</div>\n</a>\n</h4>\n</header>\n<article>\n(May 11)&nbsp;Confirming the media reports, Novavx(NASDAQ:NVAX)&nbsp;has delayed its plans for&nbsp;regulatory submissions for the COVID-19 vaccine in the U.S. U.K.and European Medicines Agency (EMA).<blockquote>（5 月 11 日）证实媒体报道，Novavx（纳斯达克股票代码：NVAX）已推迟向美国、英国和欧洲药品管理局 (EMA) 提交 COVID-19 疫苗监管文件的计划。</blockquote>The company now intends to file authorization for NVX-CoV2373 in Q3 2021. Novavax has beaten the consensus with its Q1 2021 financials, but the vaccine setback has hurt the shares which have&nbsp;lost nearly&nbsp;13%&nbsp;in pre-market now.<blockquote>该公司目前打算在 2021 年第三季度提交 NVX-CoV2373 的授权。Novavax 的 2021 年第一季度财务数据超出了市场普遍预期，但疫苗的挫折损害了该股，该股目前在盘前已下跌近 13%。</blockquote>Novavax has completed the enrollment of the pivotal Phase 3 trials in the U.S. and Mexico, and the final analysis is expected to be reported in Q2 2021, the company said.<blockquote>该公司表示，Novavax 已完成美国和墨西哥关键 3 期试验的注册，最终分析预计将于 2021 年第二季度报告。</blockquote>The global manufacturing capacity for the vaccine has been revised up to 100M doses per month by the end of Q3 2021, and a capacity of 150M doses per month is expected by Q4 2021.<blockquote>到2021年第三季度末，该疫苗的全球生产能力已修订至每月1亿剂，预计到2021年第四季度将达到每月1.5亿剂。</blockquote>Revenue has risen ~149x to ~$447M due to increased development work relating to NVX-CoV2373 for services performed under the agreements signed with the U.S. government and Coalition for Epidemic Preparedness Innovations.<blockquote>由于根据与美国政府和流行病防范创新联盟签署的协议，与 NVX-CoV2373 相关的开发工作有所增加，收入增长了约 149 倍，达到约 4.47 亿美元。</blockquote>With R&amp;D expenses rising ~34.9x from the previous quarter to $593M, the net loss in Q1 2021 has expanded ~8.6x from the previous year to $223M.<blockquote>随着R&amp;D费用比上一季度增长约34.9倍，达到5.93亿美元，2021年第一季度的净亏损比上一年扩大约8.6倍，达到2.23亿美元。</blockquote>However, cash and equivalents have jumped to $2B compared to $806M in 2020-year end primarily due to $772M received from advance purchase agreements recognized as deferred revenue.<blockquote>然而，现金及等价物已从 2020 年底的 8.06 亿美元跃升至 20 亿美元，这主要是由于从确认为递延收入的预购协议中收到的 7.72 亿美元。</blockquote>The previously announced timeline for the EUA (Emergency&nbsp;Use Authorization) submission was Q2 2021.<blockquote>之前宣布的EUA（紧急使用授权）提交时间表是2021年第二季度。</blockquote><img src=\"https://static.tigerbbs.com/68316eaff6bc94d588de0dd64c00496b\" tg-width=\"786\" tg-height=\"494\"><blockquote></blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128439536","content_text":"(May 11) Confirming the media reports, Novavx(NASDAQ:NVAX) has delayed its plans for regulatory submissions for the COVID-19 vaccine in the U.S. U.K.and European Medicines Agency (EMA).The company now intends to file authorization for NVX-CoV2373 in Q3 2021. Novavax has beaten the consensus with its Q1 2021 financials, but the vaccine setback has hurt the shares which have lost nearly 13% in pre-market now.Novavax has completed the enrollment of the pivotal Phase 3 trials in the U.S. and Mexico, and the final analysis is expected to be reported in Q2 2021, the company said.The global manufacturing capacity for the vaccine has been revised up to 100M doses per month by the end of Q3 2021, and a capacity of 150M doses per month is expected by Q4 2021.Revenue has risen ~149x to ~$447M due to increased development work relating to NVX-CoV2373 for services performed under the agreements signed with the U.S. government and Coalition for Epidemic Preparedness Innovations.With R&D expenses rising ~34.9x from the previous quarter to $593M, the net loss in Q1 2021 has expanded ~8.6x from the previous year to $223M.However, cash and equivalents have jumped to $2B compared to $806M in 2020-year end primarily due to $772M received from advance purchase agreements recognized as deferred revenue.The previously announced timeline for the EUA (Emergency Use Authorization) submission was Q2 2021.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":2863,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/199418654"}